Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal

Dow Jones

Apr 27

By Katherine Hamilton

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival.

Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year.

Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder.

Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%.

It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial.

Because of the high crossover rate, the data from the trial are uninterpretable, Compass said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 27, 2026 08:08 ET (12:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2630967713"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630967713\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630967713?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630967713","market":"us","top_or_hot":-1,"title":"Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n</p>\n<p>\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n</p>\n<p>\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n</p>\n<p>\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n</p>\n<p>\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n</p>\n<p>\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-27 20:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n</p>\n<p>\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n</p>\n<p>\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n</p>\n<p>\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n</p>\n<p>\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n</p>\n<p>\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPX","symbol_name":"Compass Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2630967713","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630967713","pubTimestamp":1777291680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival.Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year.Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder.Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%.It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial.Because of the high crossover rate, the data from the trial are uninterpretable, Compass said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPX":"Compass Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Compass Therapeutics胆汁癌治疗未达到总生存目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n\n\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n\n\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n\n\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n\n\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n\n\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 08:08 ET (12:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}